Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
  1. S-3 Offering Registration Statement
  2. 4 Open-market sale Chief Scientific Officer sold 129 shares at $15.93 ($2,055)
  3. 4 Open-market sale Chief Operating Officer sold 88 shares at $15.93 ($1,402)
  4. 4 Open-market sale President and CEO sold 545 shares at $15.93 ($8,682)
  5. 4 Open-market sale VP, Corporate Controller sold 416 shares at $15.93 ($6,627)
  6. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  7. 4 Open-market buy 10% owner bought 2,321,262 shares at $10.77 ($24,999,992)
  8. 4 Open-market buy 10% owner bought 2,321,262 shares at $10.77 ($24,999,992)
  9. 10-Q Report Quarterly Report
  10. 8-K Event Results of operations
  11. 8-K Event Unregistered share sale
  12. 4 Open-market sale Chief Medical Officer sold 422 shares at $8.63 ($3,642)
  13. 4 Open-market sale Chief Medical Officer sold 500 shares at $12.70 ($6,350)
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 8-K Event Other events
  17. 4 Open-market sale President and CEO sold 9,589 shares at $15.54 ($149,013)
  18. 4 Open-market sale Chief Operating Officer sold 989 shares at $15.54 ($15,369)
  19. 4 Open-market sale Chief Scientific Officer sold 1,457 shares at $15.54 ($22,642)
  20. SCHEDULE 13G/A Stake Statement of Beneficial Ownership

Page 1 of 19 · 365 filings